Another article of interest...love, Joicy
Tamoxifen hits the target in situ
[06/11/99; The Lancet (UK; Free Registration Required)]
Is there anything tamoxifen cannot do? Its activity in metastatic
breast cancer, for which tumour-response rates may be about
40%, encouraged the use of tamoxifen at an earlier stage of disease.
The drug is now a standard adjuvant treatment for women
with early breast cancer, but an overview published last year
suggests that the scope and effectiveness of the drug as an adjuvant
have been underestimated. Used properly (that is, in women with
tumours positive for oestrogen receptors [ER] and for at least 5
years), it is associated with reductions in the risk of recurrence
of cancer approaching 50%. Moreover, the previously held notion
that tamoxifen is less effective in premenopausal than in postmenopausal
women is wrong.
[NOTE: Access to certain articles on 'The Lancet' is free,
but you must first register with them. We recommend you do this at:
http://www.thelancet.com/cgi-bin/lancet/Register/pg_reg.cgi
]
The full article can be found at:
http://www.thelancet.com/newlancet/reg/issues/vol353no9169/body.commentary19
86.html
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
